Floatz logo

mln9708

Progression Free Survival

RenJi HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Progression Free Survival cohort.

Asset / SponsorPhaseRating
Capecitabine
Karen-Lise Garm Spindler
Phase 2B
Irinotecan
Grupo Hospital de Madrid
Phase 2B
Cetuximab
Grupo Hospital de Madrid
Phase 2B
Eloxatin
Sun Yat-sen University
Phase 2B
FLUOROURACILUM
Karen-Lise Garm Spindler
Phase 2B
Calcium folinate pentahydrate
Karen-Lise Garm Spindler
Phase 2CCC
Tucidinostat
Sun Yat-sen University
N/AD
Azacitidine
Sun Yat-sen University
N/AD

Same molecule, other indications

mln9708 is also rated in:

Multiple MyelomaDormant
BB
Indicative ·
66 / 100
View asset →
AmyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Higher-risk Myelodysplastic SyndromeDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →